James Moore: They call it tax inversion, we call it outrageous
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Outlook No wonder people feel cynical about the pharmaceutical industry. As Ebola rages through West Africa, and with myriad other pressing medical problems to solve, the top priority of the industry’s leaders appears to be finding new ways to outwit the taxman.
Now the US taxman is biting back, albeit tentatively. Drugs group AbbVie has decided to reconsider its planned merger with London listed Shire, which had precious little to do with the latter’s treatments and everything to do with getting its hands on Shire’s tax domicile.
Unfortunately for AbbVie, the Obama administration is trying to call time on tax inversions – the popular Wall Street wheeze of finding a foreign company to merge with so you can re-incorporate in its home territory and avoid (high) US taxes.
Unfortunately for AbbVie, the benefits are now much harder to see.
As for the Irish headquartered, Jersey registered Shire, well, there’s always the prospect of a $1.64bn (£1bn) break fee to console it. You might hope it would use that to bolster its research capabilities. If so, you’re likely to be disappointed.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments